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Abstract

Background Data: Spinal dural arteriovenous fistulas are a rare entity that, if
left untreated, can lead to considerable morbidity. Early diagnosis and effective
methods of treatment are badly needed in clinical application.
Purpose: To evaluate the clinical and radiological outcome of patients with spinal
dural arteriovenous fistulas who were treated with endovascular embolization,
with assessment of feasibility, safety and efficacy of endovascular treatment.
Study Design: A retrospective clinical case study.
Patients and Methods: A retrospective study was conducted on patients with Spinal
Dural Arteriovenous Fistulas (SDAVFs) who underwent endovascular treatment
in the period between February 2010 and February 2014 in the Departments
of Neurosurgery in Ain Shams University, Cairo and Souhag University, Souhag,
Egypt. Data were collected as regard clinical history, patient demographics, clinical
presentation, neurologic examination, and diagnostic work-up, location of the
fistula, duration of symptoms before diagnosis, treatment details, duration of
follow-up, and the functional status (gait and micturition) (preoperative and
postoperative). The study included twenty-two patients.
Results: Age ranged from 39-69 years with a mean59.3 ± 9.7 years. There were 17
males (77.3%) and 5 females (22.7%). Clinical presentations at diagnosis included
the following: lower extremity weakness was seen in 90.9%, sensory deficit
symptoms in 72.7%, back pain in 50%, and urinary symptoms in 27.3%. The average
duration of symptoms before treatment was 23.9 months. Six patients (27.7%)
had a progressive stepwise worsening of symptoms. Endovascular treatment
was successful in twenty patients (90.9%). There was 5% treatment-related
complication. The mean interval follow up was 18 months. Recurrence occurred in
two cases (10%) that needed further endovascular embolization without further
morbidity. According to preprocedure and postprocedure Aminoff & Logue’s
Scale of disability (ALS), improvement in gait was seen in 55% and, stabilization
of gait in 45%, gait improvement was statistically significant, while Improvement
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in micturition disorder was seen in 25% and, stabilization in 75%, micturition disorder improvement was
statistically insignificant.
Conclusion: Endovascular embolization of SDAVF with cyanoacrylate glue was technically feasible in 90.9%
of patients, relatively safe with low morbidity (5 % transient) and efficient with high favorable outcome,
with statistically significant improvement in patients’ gait disability by almost one grade at follow-up, and
micturition disorder improved in posttreatment follow up yet not statistically significant.
Key words: Spinal dural arteriovenous fistula, endovascular embolization, outcome.

Introduction
SDAVFs consist of an abnormal shunt between
a dural artery branch and a radicular vein at dural
sleeve of the nerve root, leading to increased
pressure in the venous system with consecutive
venous congestion. Despite its rarity, SDAVF is the
most common type of spinal vascular malformation,
accounting for 70% of the vascular lesions involving
the spinal cord. Patients often experience nonspecific
symptoms.14,20,21,36 The time between the onset of
symptoms and diagnosis of the lesion is usually
late in the disease course. This is because of the
nonspecific clinical presentation.16,24 Patients may
present with gait disturbances, difficulty climbing
stairs, sensory symptoms, and even radicular pain
that may affect 1 or both extremities. The neurologic
symptoms show progression with time.18 Bowel
and bladder incontinence, erectile dysfunction,
and urinary retention are seen late in the course of
the disease process.37 If the lesion is not treated,
50% of patients will become severely disabled and
less than 10% will be able to walk independently
after 3 years.9 Favorable outcome depends on the
progression of neurologic deficits at the time of
diagnosis, which makes early diagnosis preferable.15
SDAVFs can be treated by surgery with clip placement
or coagulation of the vein from a posterior spinal
laminectomy approach.33 Endovascular embolization
is an effective therapy in the treatment of SDAVFs
and can be used as a definitive intervention in most
patients.30 The success of endovascular treatment is
believed to be dependent on complete occlusion of
the proximal radicular draining vein and the site of
the fistula itself. The goal of treatment, regardless of
the type of intervention, is to eliminate the abnormal
arteriovenous communication to avoid progression
or worsening of the neurologic symptoms. 30 The
aim of this study was to evaluate the clinical and
radiological outcome of patients with SDAVFs
that were primarily treated with endovascular
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embolization in our institutions, with assessment
of feasibility, safety and efficacy of endovascular
treatment.

Patients and Methods
A retrospective study was conducted on patients
with SDAVF who underwent endovascular treatment
in the period between February 2010 and February
2014 in the Departments of Neurosurgery in Ain
Shams University, Cairo and Souhag University,
Souhag, Egypt. The medical records of these patients
were retrospectively reviewed. Data were collected
as regard clinical history, patient demographics,
clinical presentation, neurologic examination, and
diagnostic work-up, location of the fistula, duration
of symptoms before diagnosis, treatment details,
duration of follow-up, and the functional status
(preoperative and postoperative). Functional status
(gait and micturition) was measured by use of the ALS3
shown in table 1, it was calculated retrospectively
from the preoperative and postoperative clinical
notes. The interval between the onset of initial
symptoms and diagnosis of SDAVF by angiography
was calculated at the time of diagnosis.
Spinal angiography was performed before
and after treatment in all patients. It included a
study of the site of the artery of Adamkiewicz,
its involvement in the fistulous supply, its venous
drainage and search for its delayed venous filling
(indication of venous congestion interfering with
normal venous drainage, which is normally ≤ 12
seconds). Also complete evaluation of the fistula:
as regard feeders and venous drainage was done.
Digital subtraction angiography (DSA) runs were
performed to improve fistula and venous drainage
visualization, and identify any contraindications of
embolization, such as the presence of an anterior
or posterior spinal artery arising from the same
pedicle or a neighboring one to form a common
trunk. If no fistula was found after selective thoracic
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and lumbar injections, and delayed venous filling
was present at the artery of Adamkiewicz territory,
comprehensive selective spinal angiography was
performed, including injection of common carotid,
vertebral, thyrocervical, costocervical, and internal
iliac arteries.
All suspected lesions on MR imaging were
confirmed by DSA. Preoperative MR imaging was
performed in all patients. Postoperative MR imaging
was available for 12 patients. If available, preand posttreatment imaging characteristics were
compared. The treatment strategy was identical for
all patients; an attempt of endovascular obliteration
was the first choice of treatment. Surgery (in two
cases) was offered whenever embolization failed or
was abandoned for technical reasons.
Technique of Endovascular Embolization:
All spinal angiograms were performed with the
patients under general endotracheal anesthesia
to avoid patient discomfort and minimize motion
artifacts. Patients were placed supine on the
angiographic table, and transfemoral access and
sheath placement was obtained by use of a modified
Seldinger technique. All patients were given
intravenous heparin (70 U/kg–100 U/kg) to maintain
an activated coagulation between 250 and 300 s.
Spinal angiography was performed in all patients to
identify the anterior and posterior spinal arteries
and the site of the fistula. After the diagnostic
portion of the procedure, a 4F or 5F catheter was
placed in the segmental artery supplying the SDAVF.
Coaxially, through the catheter an Excelsior SL 10
(Stryker, Neurovascular, Raynham, Massachusetts),
Magic (Balt, Montmorency, France), Echelon 10 (ev3
Neurovascular, Irvine, California), or Marathon (ev3
Neurovascular) microcatheter was advanced under
road mapping over a microwire to reach the most
distal aspect of the segmental artery supplying the
SDAVF. Microcatheter superselective angiography
was performed to determine microcatheter position
and if there was filling of the anterior spinal,
posterior spinal, or a radiculomedullary artery.
Endovascular embolization of the SDAVF was
performed with cyanoacrylate glue: n-BCA (Codman
Neurovascular), Glubran 2 (GEM, Viareggio, Italy),
or Histoacryl (Braun, Melsungen, Germany), with
Lipidol in a diluted mixture of 25-75% .The aim of
the embolization was to deliver the liquid embolic
agent into the proximal draining vein while occluding
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the fistula site and feeding arterial vessels. After
injection and delivery of the embolic agent, the
microcatheter was quickly removed to prevent its
adhesion to the vessel wall. Repeated segmental
angiography after embolization was performed
bilaterally at the level of the arterial feeder and
the adjacent 2 segmental levels above and below
the site of the fistula. Venous phase response of
the artery of Adamkiewicz was also evaluated by
use of control angiography (normal ≤ 12 second).
If the fistula persisted after embolization, surgical
recommendation was made. After the procedure,
the patient was admitted to the neurointensive care
unit for close monitoring for 24–48 hours.
If the patient’s physical examination was worse
after embolization, spinal MR imaging and another
spinal angiogram were performed. If the repeat
spinal angiogram revealed no residual fistula and an
exceptional second fistula could not be identified,
patients were treated with anticoagulants, steroids,
and hypertensive volume expansion therapy. During
follow-up spinal angiography, selective spinal
angiography was performed.
Follow-Up:
Occlusion of the fistula was confirmed by repeated
spinal angiography in all patients before discharge
from the hospital. Spinal angiogram and MR imaging
were obtained at 12 months after treatment in all
patients; however, we were only able to review the
follow-up MR imaging results in 12 patients. If there
was a delay in recovery or a clinical deterioration or
recurrent symptoms, MR imaging and angiography
studies were repeated immediately.
Statistical Analysis:
Software program SPSS version 16 was used for
statistical analysis of data, qualitative variables
as numbers and percentages, and quantitative
variables as mean and SD. The nonparametric
Wilcoxon signed rank test was used to compare preand posttreatment ALS gait and micturition scores, P
values < .05 were considered significant.

Results
Between February 2010 and February 2014 in
the Departments of Neurosurgery in Ain Shams
University and Souhag University a total of twentytwo patients were treated for an SDAVF. Our study
population, age range from 39-69 years with a mean
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59.3 ± 9.7 years, there were 17 males (77.3%) and 5
females (22.7%). Diagnosis of SDAVF was confirmed
by spinal angiography. Twenty-two patients were
primarily treated by an endovascular approach.
Endovascular treatment was feasible in 20 patients
(90.9%) while failures occurred in 2 cases and were
referred to surgery.
Clinical Data:
Table 2 shows clinical presentation at diagnosis. Most
common Clinical presentations at diagnosis included
the following: of the 22 patients, lower extremity
weakness was seen in 20 patients (90.9%), sensory
deficit symptoms in 16 (72.7%), back pain in 11
(50%), and urinary symptoms in 6 (27.3%), lastly was
defecation disorder and sexual dysfunction each in 4
(18.2%). The average duration of symptoms before
treatment was 23.9 months (range, 2–62 months).
Six patients (27.7%) had a progressive stepwise
worsening of symptoms. In this series, there were 2
sacral, 4 lumbar, 10 low thoracic (T8–T12), and 6 mid
thoracic fistulas (T4–T7). Most of the fistulas had a
single segmental arterial feeding artery; however,
there were 2 fistulas that demonstrated multiple
feeding arteries.
Treatment:
Endovascular treatment was successful in twenty
(90.9%) of the twenty-two patients, while in two
patients (9.1%) initial embolization failed, one due
to failure to have a stable distal position for the
injection, and the other the glue was proximal to
occlude the intradural draining vein completely with
closure of the feeder, as documented by control
angiogram and persistent filling of the fistula via
collateral circulation that couldn’t be accessed by
endovascular approach. Both cases were referred to
surgical treatment.
There was one treatment-related complication.
One patient had clinical deterioration of clinical
symptoms after penetration of the embolic material
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to a trans-medullary anastomosis may be connected
to the anterior spinal artery; however, this improved
after administration of heparin, steroids and
hypertensive measures.
The mean interval follow up was 18 months
(range, 6–36 months). Our clinicoradiological results
will be applied to the twenty patients who received
endovascular treatment with exclusion of the 2
patients referred to surgery.
According to preprocedure and postprocedure
ALS, improvement in gait was seen in 11 (55%) of 20
patients, stabilization of gait in 9 (45%). One patient
experienced worsening of gait ALS post procedural,
this patient’s symptoms probably worsened
because of penetration of embolic material too
far into the venous system, yet he was treated by
steroids, heparin and increasing blood pressure to
show improvement to base line. Two (10%) of the 20
patients (with endovascular treatment) underwent
repeated embolization. In these 2 patients, clinical
deterioration at follow-up at 6, 10 month, prompted
a repeated diagnostic angiography study revealing
a persistent SDAVF, which was treated with
subsequent embolization. On final follow-up, both
patients improved clinically based on ALS gait and
micturition scores. Therefore, all patients (100%)
who received endovascular treatment had either
improvement or unchanged outcome. Improvement
in micturition was seen in 5 of 20 patients (25%)
and micturition stabilized 15 of 20 patients (75%),
respectively. Comparing pre- and last follow-up
post-treatment disability in quantitative terms for all
embolized patients, mean ALS gait disability grade
improved and was statistically significantly (2.3±1.3
versus 3.1±1.2 [P =. 0008]). Mean micturition grade
improved but was not statistically significant (1.4±
0.9 versus 1.6±1.0 [P=. 27]). (Data were summarized
in table 3)
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Table 1: Aminoff & Logue’s Disability Scale3

Gait
G0
G1
G2
G3
G4
G5

Micturition

Normal
Leg weakness, abnormal gait or stance,
restricted activity
Restricted activity but no support required
One stick required for walking
Two sticks , crutches , or frame required
for walking
Confined to wheelchair

M0
M1
M2
M3

Normal
Infrequent hesitancy or urgency , altered
sensation , but continent
Occasional urinary incontinence or retention
Total incontinence or persistent retention

Table 2: Symptom distribution at time of Diagnosis

Symptom at Diagnosis
Back Pain

11 (50%)

Leg weakness

20(90.9%)

Sensory Deficit

16 (72.7%)

Micturition Disorder

6 (27.3%)

Defecation Disorder

6 (27.3)%

Sexual dysfunction

4 (18%.2%)

A

B

C

E

F

G

D

H

Figure 1. a-h. A Case of 54-years-old Male with bilateral lower extremity weakness, urinary disorder and
sexual dysfunction a, b: Spinal Digital Subtraction Angiography (DSA) Antroposterior view (AP) with injection
of right 6th thoracic intercostal artery, filling of a SDAVF with pial venous drainage. c, : Spinal DSA , AP view
with injection of left 11th thoracic intercostal artery, filling of artery of Adamkiewicz ( anterior spinal artery
contribution). d, e Spinal DSA AP with superselective injection of the fistula feeder ,showing the fistulous site
and draining pial veins. f, Subtracted images AP Spine view, showing the glue cast occluding draining vein and
fistula refluxing into the feeder. g, Spinal DSA AP view control injection showing no more filling of the fistula
with glue cast occluding draining vein and fistula refluxing into the feeder. h, same as g but subtracted images.
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B

E

C

F

D

G

H

Figure 2 a-h. A Case of 64-years-old, Male with bilateral lower extremity weakness, urinary disorder, defecation
dysfunction. a, MRI dorsal spine , sagittal T2 weighted images showing medullary signal from thoracic 6 down
to conus, associated with a tuft with abnormal tortuous flow signal voids overlying the dorsal aspect of the
cord at levels of thoracic 8,9,10,suggesting SDAVF. b : Spinal DSA , AP view with injection of left 9th thoracic
intercostal artery, filling of artery of Adamkiewicz ( anterior spinal artery contribution). c,d: Spinal DSA AP
with injection of right 10th thoracic intercostal artery, filling of a SDAVFwith pial venous drainage. e :Spinal
DSA AP with superselective injection of the fistula feeder, showing the fistulous site and draining pial veins.
e, Subtracted images AP Spine view, showing f,g, Spinal DSA AP view control injection showing no more filling
of the fistula with the glue cast occluding draining vein and fistula refluxing into the feeder. h : Spinal DSA, AP
view with injection of left 9th thoracic intercostal artery, showing good filling of artery of Adamkiewicz posttreatment
Table 3: AL functional Grades, before and after intervention for 20 patients did endovascular embolization

AL
Gait
AL
Mic.

Post
Improvement
11/20
(55%)
5/20
(25%)

Post
Unchanged
9/20
(45%)
15/20
(75%)

Discussion
SDAVFs arise from a spontaneous or acquired
abnormal communication between a segmental
radicular artery and the corresponding radicular vein
at its site of dural penetration. SDAVFs are relatively
rare, and their diagnosis is often missed because of
nonspecific clinical symptoms at presentation.12,13,19
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Post
Worsen

Mean, SD
Pre

Mean, SD
Post

Sig

-----------

3.2±1.4

2.4±1.4

.008 SS

----------

1.7±1.1

1.4±1.0

0.28

The delay to diagnosis in our patients 23.9 months
(range, 6–36 months) is comparable to other
series.11,13,14,23 We did not correlate the severity of
the clinical presentation with the time of diagnosis.
Most of the patients in our study were males 77.3%
(17 patients) with an average age of 59.3± 9.7.This
finding also correlates with the demographics seen
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in several other large studies.14,19,23 We had only one
patient younger than 40 years in our study, which
illustrates the rarity of this diagnosis in the younger
patient population.
Presenting symptoms in our patient population
included the following: lower extremity weakness
was seen in 20 patients (90.9%), sensory deficit in 16
(72.7%), back pain in 11 (50%), and urinary symptoms
in 6 (27.3%), lastly was defecation disorder and
sexual dysfunction each seen in 4 patients (18.2%).
These symptoms at clinical presentation are similar
to those reported in other large series.11,14,23,24,32
Development of upper motor neuron signs with
gait and micturition impairment is usually seen late
in the course of the disease process. Early diagnosis
and successful treatment of the fistula correlates
with improvement in clinical symptoms.6 Even with
successful treatment, late presentation is associated
with poor clinical and functional outcomes. Also in
accordance with previous studies, most SDAVFs in
our series originated from the thoracic and lumbar
levels.14,22,23
Several prior studies have reported results after
endovascular treatment of SDAVFs. Niimi et al,25
reported 49 patients who were primarily treated
with n-BCA, but isobutyl-2-cyanoacrylate and
polyvinyl alcohol were also used. According to those
authors, adequate embolization was achieved in 39
patients (80%); however, angiographic recurrence
was seen in 8 (23%) of the 35 patients.25 Westphal
and Koch40 found recurrent fistulas in 20 (57%) of 35
patients treated with embolization at a mean followup time of 7.5 months. In another reported series of
27 SDAVFs, Song et al31 showed a 25% failure rate in
patients treated with n-BCA.
Furthermore, several studies have reported
outcomes after embolization of SDAVFs. Eskander et
al,10 reported on their experience in 26 consecutive
patients who were treated for a 6-year period.
Nine (39%) of the 23 patients in whom liquid
acrylic embolization was performed or attempted
ultimately required surgery.10 All patients were
stabilized or their condition improved after
definitive treatment, as assessed by the ALS.10 Van
Dijk et al,37 reported a cure rate of only 25% (11/44
patients) after treatment with n-BCA embolization.
After failed endovascular treatment, 31 patients
were cured surgically; the 2 other patients refused
surgery.37 Motor and bladder function scores were
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significantly improved in 35 patients who had long
term follow-up (both P < .005).37 Sherif et al,29 in
their study of 26 patients in which embolization with
Histoacryl was performed in 19 patients (73.1%)
and direct surgery in 7 patients (26.9%), reported
a statistically significant improvement was seen in
both the mRS score and the ALS gait scale score (P
< .05). In addition, Andres et al4 in a group of 21
patients showed that surgical and endovascular
treatment resulted in significant improvement in
ALS scores (62.5% and 31.4%, respectively; P < .05).
Furthermore, Narvid et al,24 in a group of 63 patients
in whom 39 were treated by an endovascular
approach and 24 by a surgical approach, reported a
significant improvement was observed in ALS scores
in both the endovascular and surgery groups (gait,
P < .001; micturition, P= .005). Gemmete et al11
in their study of 38 patients reported a significant
improvement was observed in ALS scores for gait
and micturition in patients treated by both glue and
Onyx, with a 17% failure rate.
Symon et al, 34 reported a series of twenty
surgically treated patients who were followed up
beyond 3 years, with follow-up ranging from 3 to
24 years. They found that at 18 to 36 months after
surgery, improvement (particularly regarding gait)
and stabilization of total disability (gait, micturition,
and bowel control) was documented in 84% of
patients. However, at last follow-up (mean, 147
months), only 35% of available patients were
improved or stabilized. In this series investigators
assessed overall disability without investigating its
components separately.34,35 Oldfeild et al,28 reported
a series of 19 patients were followed up a mean of
37 months. They showed a significant improvement
of less than one grade (0.4) in mean gait disability
at last follow-up. In this series investigators did not
investigate micturition disability.1,28
In our study, Endovascular treatment was
successful in 20 out of 22 (90.9%), and failure
occurred in 2 out of 22 patients, (9.1%) who were
referred to surgery. We had only one patient
(5%) out of 20 patients who had endovascular
procedures, with procedure related complication in
the form of worsening of symptoms post treatment
that improved later on. Two patients had recurrence
(10%) that needed further treatment without
further morbidity. We had improvement in gait seen
in 11 (55%) of 20 patients, stabilization of gait in 9
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(45%), Improvement in micturition was seen in 5
of 20 patients (25%) and micturition stabilized 15
of 20 patients (75%), respectively. ALS gait scores
showed improvements after treatment, mean ALS
gait disability grade was (2.3±1.3 versus 3.1±1.2
[P = .0008]), this improvement was statistically
significant (P < .05, Wilcoxon signed rank test), while
ALS micturition scores showed improvement, (1.4±
0.9 versus 1.6±1.0 [P =. 27]) but was not statistically
significant. Our study compares favorably with the
other reports described above.
The goal of treatment of SDAVF is to arrest
neurologic deterioration. Studies have shown no
significant correlation with duration of symptom
onset and the extent of cord edema on MR imaging.2,32
A trend has suggested that earlier exclusion of the
fistula correlates with improved motor function.30
In general, studies suggest that bladder function,
if affected, does not recover.6,17,32 In our study
improvement in motor function after treatment was
more likely to occur than improvement in micturition
dysfunction.
In our study, the time from symptom onset to
diagnosis of the SDAVF was 23.9 months. This
finding may have influenced our results because,
even with proper treatment, a long duration of
initial neurologic symptoms is associated with poor
clinical and functional outcomes.33
In our study, there was only a 9.1% (n=2/22)
failure rate after embolization and a low recurrence
rate of 10% of the treated cases (n=2/20), which is an
improvement for endovascular treatment compared
to the studies described above. Such a rate may be
the result of improvements in diagnostic imaging,
a better understanding of the pathophysiology of
SDAVFs, further developments in microcatheter and
microwire technology, or the technical experience
of the operators regarding use of liquid embolic
agents.
Ethylene vinyl alcohol (Onyx) is a relatively
new liquid embolic agent used to treat cerebral
arteriovenous malformations and fistulas. 8,27,39
Because of the physical properties of the agent, this
may allow a longer, more controlled injection with
better penetration of the vascular bed (i.e, venous
aspect of the fistula) compared with conventional
liquid agents, which polymerize immediately on
contact with blood. Gemmete et al,11 in their series
had a 10% (2/20) failure rate with cyanoacrylate glue
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( close to our failure rate 9.1%) and a 33.3% (3/9)
failure rate with Onyx. This finding may be related to
the experience the authors have with the injection
of glue. Since 2003, a total of 3 small case series
have described the use of Onyx in the treatment of
SDAVFs.8,26,38 To the best of our knowledge, Gemmete
et al,11 series of 9 patients, in whom SDAVF was
treated with Onyx, is the largest to date. We did not
use onyx in our series, due to limited experience
using it in spinal lesions, as well as safety concerns
since it needs a safe area for possible reflux, which
is not always possible with SDAVF. Additionally it
could not be diluted to reach distally the foot of the
vein, and this may lead to higher rates of failure and
recurrence. This is in accordance with the high rate
of failure reported by others, up to 33% by Gemmete
et al,11 when compared to this series’ failure rate of
10 % with Glue.
Patients should be monitored with clinical
examination and MR imaging after treatment;
however, at present no statistical data suggested
correlation between resolution of T2-weighted
cord hyperintensity and clinical outcome. The
persistence of flow voids despite treatment should
prompt further spinal angiography to exclude
persistent fistula from the same or adjacent level
with collateral flow.2,5,7,32
In our study 6 out of 12 patients (50%) with
available MRI, experienced complete resolution of
flow voids/vessels within the spinal canal, whereas
Song et al,31 reported a 73% resolution of flow voids/
vessels within the spinal canal after successful
treatment in their series. Our imaging findings are
similar to those reported in the previous literature.2,7,5
Limitations of our study were the relatively small
sample and the retrospective, design. Furthermore,
pre- and post-MR imaging studies were not available
in 40% of patients with successful endovascular
treatment.

Conclusion
Endovascular embolization of SDAVF with
cyanoacrylate glue was technically feasible in 90.9%
of patients, relatively safe with low morbidity (5
% transient) and efficient. There was a high rate
of favorable outcome, with statistically significant
improvement in patients’ gait disability by almost
one grade at follow-up. Micturition disorder also
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showed a statistical trend towards improvement in
posttreatment follow up. Recurrence occurred only
in 10%. Although endovascular embolization can
result in good clinical outcomes, offers the benefits
of less invasiveness and earlier rehabilitation.
Surgery remains the treatment of choice when safe
embolization of the proximal radicular draining vein
cannot be obtained or in the event that the shunting
artery of the SDAVF also supplies the anterior spinal,
posterior spinal, or radioculomedullary artery.
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الملخص العربي
النواسـير الشـريان  -وريديـة للأم الجافيـة الشـوكية السـحائية :النتائـج السـريرية واإلشـعاعية للعلاج مـن خلال
األوعية
البيانـات الخلفيـة :أن الناصـور الشـوكى الشـريانى الوريـدى السـحائى مـرض نـادر الحـدوث ،تركـه بـدون علاج يـؤدى إلـي
مضاعفات جسيمة  .التطبيقات الطبية فى أشد الحاجة لتشخيص مبكر وطرق عالج متعددة لهذا المرض.
الهـدف :تقييـم النتائـج األكلينيكيـة واألشـاعية لمرضـى الناصـور الشـريان الوريـدى الشـوكى السـحائى الـذى تـم عالجهـم
بالعالج التداخلى للشرايين  ،مع تحديد مدى أمان وفاعلية و جدوى هذا العالج.
طـرق البحـث :تـم عمـل دراسـة اسـتعادية علـى مرضـى الناصـور الشـوكى الشـريانى الوريـدى السـحائى الذيـن اجـرو علاج
تداخلى فى الفترة من فبراير  ٢٠١٠إلى فبراير  ٢٠١٤وذلك بقسم جراحة المخ واألعصاب بمستشفيات جامعة عين شمس
و جامعـة سـوهاج .تـم تجميـع البيانـات مـن السـجالت الطبيـة للمرضـى فيما يخـص التاريخ الطبى ،العـرض األولى للمريض،
الفحـص العصبـى ،الفحوصـات التشـخيصية ،مـكان الناصـور ،مـدة األعـراض الطبيـة ،العلاج ،األسـتنتاج  ،المتابعـة الطبيـة،

الحالـة الوظيفيـة للمشـى والتبـول مـا قبـل ومـا بعـد العلاج .اثنـان وعشـرون مريـض تتـراوح اعمارهـم مـن  ٣٩إلـى  ٦٥عـام
ومتوسط العمر  ،٣,٥٩سبعة عشر ذكر ( ) ٪ ٣,٧٧وخمس سيدات (. ) ٪ ٧,٢٢
النتائـج :اكثـر األعـراض المرضيـة حدوثـاً كان الخـزل بالطرفيـن السـفليين فـى  %٩,٩٠مـن الحـاالت ،اآلم الظهـر فـى ،% ٥٠
وإضطرابـات التبـول فـى  . % ٣,٢٧متوسـط مـدة األعـراض  ٩,٢٣شـهر .سـتة مرضـى (  )% ٣,٢٧كانـوا يعانـون مـن تدهـور

باألعراض المرضية ،نجح العالج التداخلى فى عشرون مريض  %٩,٩٠ ،من الحاالت  .المضاعفات المؤقتة حدثت فى .% ٥
متوسط المتابعة الطبية كان ١٨شهر  .ارتجاع المرض حدث فى  % ١٠مما أستلزم عالج تداخلى مرة أخرى دون مضاعفات
جديدة .حدث تحسن وظيفى فى المشى فى  % ٥٥من الحاالت بينما استقر فى  % ٤٥و كان التحسن ذو دالله إحصائية،
وحدث تحسن وظيفى فى التبول فى  % ٢٥من الحاالت بينما استقر فى  % ٧٥من الحاالت و لم يكن ذو دالله احصائية.

اإلسـتنتاج :غلـق الناصـور الشـوكى الشـريانى الوريـدى السـحائى عـن طريـق الحقـن بواسـطة العلاج التداخلـى للشـرايين
اثبتت جدواة فى  %٩,٩٠من الحاالت وكان امن ذو نسبة مضاعفات قليلة نسبياً و تحسن وظيفى فى المشيه ذو داللة

احصائية كبيرة ،مع تحسن وظيفى فى التبول ولكن دون داللة أحصائية .تبقى الجراحة بديل لبعض الحاالت التى ال يمكن
عالجها بأمان.
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